ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is a clinical-stage immunology focused biopharmaceutical company headquartered in Singapore. The company, founded in 2010, is dedicated to developing innovative treatments to enhance the lives of patients. ASLAN is actively involved in the development of eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis, and farudodstat, a potent oral inhibitor of the enzyme DHODH, as a potential first-in-class treatment for alopecia areata. The company operates from San Mateo, California and Singapore. In its most recent funding round on 13 March 2024, ASLAN Pharmaceuticals secured a $5.00M Post-IPO Equity investment. The investors contributing to this funding round were not specified. For more information, visit www.aslanpharma.com. ASLAN Pharmaceuticals represents a promising player in the biotechnology, health care, and pharmaceutical industries and exhibits potential for significant growth and impact in the healthcare sector.